应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NTRA Natera, Inc.
交易中 07-18 13:37:21 EDT
101.38
-8.99
-8.15%
最高
111.48
最低
99.21
成交量
193.49万
今开
111.44
昨收
110.37
日振幅
11.12%
总市值
124.49亿
流通市值
120.07亿
总股本
1.23亿
成交额
1.99亿
换手率
1.63%
流通股本
1.18亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
更新版 1-美国 FDA 顾问支持批准 Guardant 的血液癌症检验项目
Reuters · 05-24
更新版 1-美国 FDA 顾问支持批准 Guardant 的血液癌症检验项目
美国 FDA 顾问支持批准 Guardant 的癌症测试
Reuters · 05-24
美国 FDA 顾问支持批准 Guardant 的癌症测试
TD Cowen:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由123.00美元调整至137.00美元。
智通财经 · 05-11
TD Cowen:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由123.00美元调整至137.00美元。
BUZZ-Natera 在发布第一季度业绩预增报告后一跃而起
Reuters · 05-10
BUZZ-Natera 在发布第一季度业绩预增报告后一跃而起
美国研究综述-Cerence、Epam Systems、Progyny
Reuters · 05-10
美国研究综述-Cerence、Epam Systems、Progyny
美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司
Reuters · 03-06
美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司
美国研究综述-树皮、Fleetcor Technologies、特斯拉
Reuters · 03-05
美国研究综述-树皮、Fleetcor Technologies、特斯拉
Natera Inc 预计每股亏损 73 美分 - 财报前瞻
Reuters · 02-27
Natera Inc 预计每股亏损 73 美分 - 财报前瞻
更新 2-基因测试制造商 Invitae 准备破产 - 华尔街日报
Reuters · 02-06
更新 2-基因测试制造商 Invitae 准备破产 - 华尔街日报
BUZZ-CareDx 在专利审判中被陪审团判给同行 Natera 9,600 万美元后下跌
Reuters · 01-29
BUZZ-CareDx 在专利审判中被陪审团判给同行 Natera 9,600 万美元后下跌
BUZZ-完成向 Natera 出售生殖健康资产后,Invitae 实现增长
Reuters · 01-22
BUZZ-完成向 Natera 出售生殖健康资产后,Invitae 实现增长
公司概况
公司名称:
Natera, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Natera, Inc.于2007年1月在特拉华州成立。该公司是一个发展迅速的诊断公司且专有的分子生物学和生物信息学技术正在部署变更管理的遗传疾病。其新颖的分子检测能可靠地测量整个基因组区域的样本,小到一个单细胞。他们的统计算法结合这些测量,可以从更广泛的科学界提供数据,以检测各种最佳的一流的准确度和覆盖面严重情况。在产前检查空间,他们的技术已被证明有临床性和商业性。除了直接在美国的销售,该公司正在继续扩大,他们在全球有接近90个实验室和分销合作伙伴,包括许多大型的国际实验室。他们甚至能够更广泛地采用技术通过引入一个全球性的基于云的分布模型。该公司自2009推出七款分子诊断测试,他们打算在未来推出新产品,在产前检查和肿瘤领域。2013年三月,他们推出Panorama,一种无创性产前测试,或NIPT。
发行价格:
--
{"stockData":{"symbol":"NTRA","market":"US","secType":"STK","nameCN":"Natera, Inc.","latestPrice":101.375,"timestamp":1721324230169,"preClose":110.37,"halted":0,"volume":1934930,"delay":0,"floatShares":118441970,"shares":122802694,"eps":-3.116722,"marketStatus":"交易中","marketStatusCode":2,"change":-8.995,"latestTime":"07-18 13:37:21 EDT","open":111.44,"high":111.4799,"low":99.21,"amount":199193710.1153,"amplitude":0.111171,"askPrice":101.61,"askSize":109,"bidPrice":101.26,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-3.116722,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721332800000},"adr":0,"listingDate":1435809600000,"adjPreClose":110.37,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":110.95,"preClose":110.37,"latestTime":"09:20 EDT","volume":2,"amount":221.9,"timestamp":1721308812119},"postHourTrading":{"tag":"盘后","latestPrice":110.37,"preClose":110.37,"latestTime":"19:59 EDT","volume":316064,"amount":34884028.29,"timestamp":1721260778499},"volumeRatio":2.30967,"impliedVol":0.6682,"impliedVolPercentile":0.8333},"requestUrl":"/m/hq/s/NTRA/wiki","defaultTab":"wiki","newsList":[{"id":"2437166987","title":"更新版 1-美国 FDA 顾问支持批准 Guardant 的血液癌症检验项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2437166987","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437166987?lang=zh_cn&edition=full","pubTime":"2024-05-24 04:45","pubTimestamp":1716497104,"startTime":"0","endTime":"0","summary":" 路透5月23日 - 美国食品和药物管理局的顾问们周四建议批准Guardant Health公司的 血液检验用于检测始于结肠或直肠的癌症。专家组以七比二的赞成票通过了这项名为 \"盾牌 \"的结肠直肠癌检测。如果获得批准,Shield 将成为继 Epigenomics 公司的 Epi proColon之后,美国第二种基于血液的 CRC 诊断检验。据美国食品和药物管理局称,美国每年约有 15 万例 CRC 患者,是美国癌症死亡的第二大原因,每年有 5 万多人死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","NTRA","BK4548","EXAS","BK4588","BK4551","LU0266013472.USD","LU1861558580.USD","LU0053671581.USD","BK4196","LU1861559042.SGD","GH","BK4139"],"gpt_icon":0},{"id":"2437716320","title":"美国 FDA 顾问支持批准 Guardant 的癌症测试","url":"https://stock-news.laohu8.com/highlight/detail?id=2437716320","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437716320?lang=zh_cn&edition=full","pubTime":"2024-05-24 04:41","pubTimestamp":1716496880,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透5月23日 - 美国食品和药物管理局的顾问们周四建议批准Guardant Health公司的 血液检验用于检测始于结肠或直肠的癌症。 该小组以七比二的票数支持使用这种名为 \"盾牌 \"的结肠直肠癌检测方法,认为它的益处大于风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","GH","LU0266013472.USD","BK4548","NTRA","BK4585","EXAS","BK4588","BK4196","LU0053671581.USD","BK4139","LU1861558580.USD","BK4551","LU1861559042.SGD"],"gpt_icon":0},{"id":"2434878867","title":"TD Cowen:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由123.00美元调整至137.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434878867","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434878867?lang=zh_cn&edition=full","pubTime":"2024-05-11 01:45","pubTimestamp":1715363123,"startTime":"0","endTime":"0","summary":"TD Cowen:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由123.00美元调整至137.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110145288751a847&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405110145288751a847&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TD","NTRA"],"gpt_icon":0},{"id":"2434851782","title":"BUZZ-Natera 在发布第一季度业绩预增报告后一跃而起","url":"https://stock-news.laohu8.com/highlight/detail?id=2434851782","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434851782?lang=zh_cn&edition=full","pubTime":"2024-05-10 21:46","pubTimestamp":1715348774,"startTime":"0","endTime":"0","summary":" 5月10日 - ** 基因测试公司Natera 周五早盘股价大涨13%,此前该公司公布了强劲的三季度业绩和预测。** 该公司周四晚些时候公布的 第一季度营业收入同比增长 52%,达到 3.677 亿美元,高于伦敦证交所一致预期的 3.163 亿美元。** 季度调整后每股亏损 56 美分,低于市场预期的每股亏损 71 美分。** 预计 2024 年的营业收入为 14.2-1.45 亿美元,高于之前的 13.2-1.35 亿美元的指导目标** 报告发布后,至少有 5 家券商上调了预测值,包括 Bernstein 和 TD Cowen。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","LU0053671581.USD","BK4139","NTRA"],"gpt_icon":0},{"id":"2434855383","title":"美国研究综述-Cerence、Epam Systems、Progyny","url":"https://stock-news.laohu8.com/highlight/detail?id=2434855383","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434855383?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:39","pubTimestamp":1715344798,"startTime":"0","endTime":"0","summary":" 路透5月10日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价,其中包括 Cerence、Epam Systems 和 Progyny。要闻 * Cerence Inc :富国银行将其评级从 \"增持 \"下调至 \"等权重\"。* Epam Systems Inc :丰业银行将其评级从 \"跑赢大市 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRCY","LU2463526074.USD","FOLD","FLNC","MKSI","EYE","FDMT","LU1815336091.USD","ANIK","LYFT","IE00B66KJ199.SGD","MGNX","GRWG","MRC","CE","CPAY","PGNY","CRNX","AVAH","MTRN","HBI","OXY","BK4227","BK4533","LU0053671581.USD","ACAD","BK4113","BK4548","FWRD","CMI","IFF","OBDC","CRL","GAIN","YOU","BK4539","GFF","NTLA","ARHS","GO","BK4109","HLIO","LU0320765992.SGD","EPAM","LU0823414478.USD","BIGC","ARWR","BRT","NTRA","APLT"],"gpt_icon":0},{"id":"2417239460","title":"美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2417239460","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417239460?lang=zh_cn&edition=full","pubTime":"2024-03-06 14:48","pubTimestamp":1709707680,"startTime":"0","endTime":"0","summary":" 路透社3月6日 - 华尔街证券分析师周三调整了对 Arrivent Biopharma、Ferguson 和 Target 等几家美国上市公司的评级和目标价。要闻 * Arrivent Biopharma Inc :杰富瑞给予买入评级 * 弗格森 :杰富瑞将目标价从 222 美元上调至 244 美元 * Target Corp :汇丰银行将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EHAB","ATIP","LFST","NNN","NKTR","DYN","LU0348723411.USD","PLAY","BOX","BK4023","FLGT","BK4588","AVAV","HCP","MD","NTST","NTRA","APGE","ROST","TSLA","AXGN","LU2272731600.USD","STIM","NWPX","CRWD","JWN","CRGY","BK4144","LU0053666078.USD","LU0823411888.USD","VYX","TWLO","MCRB","BK4585","FWRG","LU1244550577.SGD","FERG","LU0823414478.USD","LU0082616367.USD","BASE","COLB","LII","LU2272731782.SGD","TRGP","IONS","TGT","SG","AVBP","CTKB","AGS"],"gpt_icon":0},{"id":"2417200459","title":"美国研究综述-树皮、Fleetcor Technologies、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2417200459","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417200459?lang=zh_cn&edition=full","pubTime":"2024-03-05 14:57","pubTimestamp":1709621845,"startTime":"0","endTime":"0","summary":" 路透社3月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括 Bark、Fleetcor Technologies 和特斯拉。要闻 * Bark Inc :杰富瑞将其评级从 \"持有 \"上调至 \"买入\";将交易价从1.54美元上调至1.9美元。* Fleetcor Technologies Inc :贝尔德将其评级上调至 \"跑赢大盘\"。* 特斯拉 :加拿大皇家银行将目标价从297美元上调至298美元 以下是路透社周二报道的美国公司研究报告摘要。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SFIX","XPOF","DSP","HSIC","SWTX","NTRA","LU0011850046.USD","BLUE","GWW","LU1861558580.USD","BK4099","COST","TSLA","PDCO","APG","LU1839511570.USD","PAY","LU0097036916.USD","CCOI","PCAR","RNA","IE0004445015.USD","APLS","MGX","AMRC","LU0310799852.SGD","HGV","CCCC","UNH","BK4097","HIMS","BK4149","LU1496350171.SGD","FLT","BLD","AKRO","LU1720051017.SGD","GTLB","BARK","NUVL","SQSP","AKYA","LU1670628061.USD","PNTG","CQP","IBP","PLNT","AMPH","TSLL","PRVA"],"gpt_icon":0},{"id":"2414886951","title":"Natera Inc 预计每股亏损 73 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2414886951","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414886951?lang=zh_cn&edition=full","pubTime":"2024-02-27 06:49","pubTimestamp":1708987784,"startTime":"0","endTime":"0","summary":" * Natera公司 将于2月28日发布截至2023年12月31日的季度业绩报告,预计该公司的季度收入将有所增长。* LSEG 分析师对 Natera Inc 的平均预期是每股亏损 73 美分。* 华尔街对 Natera Inc 的 12 个月目标价中位数为 78.00 美元,高于上一交易日的收盘价 70.46 美元。2月26日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"gpt_icon":0},{"id":"2409456077","title":"更新 2-基因测试制造商 Invitae 准备破产 - 华尔街日报","url":"https://stock-news.laohu8.com/highlight/detail?id=2409456077","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409456077?lang=zh_cn&edition=full","pubTime":"2024-02-06 03:06","pubTimestamp":1707159971,"startTime":"0","endTime":"0","summary":" 路透2月5日 - 据《华尔街日报》周一报道,基因测试制造商Invitae 正准备在几周内申请破产。据熟悉内情的人士周一报道,基因测试制造商Invitae 正准备在几周内申请破产。报道称,这家由软银支持的 公司正在与FTI咨询公司和律师事务所Kirkland & Ellis合作,探索包括破产在内的战略选择,以解决资产负债表上15亿美元的债务问题。软银和律师事务所 Kirkland & Ellis 没有立即回应路透的置评 请求,FTI Consulting 拒绝置评。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","NTRA","NVTA","BK4139"],"gpt_icon":0},{"id":"2407865184","title":"BUZZ-CareDx 在专利审判中被陪审团判给同行 Natera 9,600 万美元后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2407865184","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2407865184?lang=zh_cn&edition=full","pubTime":"2024-01-29 21:12","pubTimestamp":1706533974,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 1月29日 - ** 医疗测试制造商CareDx 的股价盘前下跌10.2%,至8.1美元。** 遗传测试公司Natera 的发言人称,该公司周五晚些时候在特拉华州联邦法院说服了陪审团, (link),CDNA的肾移植测试侵犯了其一项专利。** 另外,NTRA周一表示, (link),陪审团已裁定CDNA赔偿其8370万美元的利润损失和1260万美元的专利使用费。 ** NTRA指控CDNA侵犯了与使用无细胞DNA评估人体排斥肾移植风险有关的专利。** 截至上周五收盘,该公司股价在过去12个月中下跌了38%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","CDNA","NTRA","BK4139"],"gpt_icon":0},{"id":"2405297036","title":"BUZZ-完成向 Natera 出售生殖健康资产后,Invitae 实现增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2405297036","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2405297036?lang=zh_cn&edition=full","pubTime":"2024-01-22 21:52","pubTimestamp":1705931527,"startTime":"0","endTime":"0","summary":" 1月22日 - ** 基因测试制造商Invitae公司 的股价盘前上涨4.9%至45美分** 该公司称,它已完成 向 Natera 出售其载体筛查和无创产前筛查设备 的交易,交易价格高达 5250 万美元。** 交易价值包括现金、里程碑付款和诉讼抵免 - NVTA**载体筛查设备用于检测某些遗传疾病遗传给婴儿的风险。** NTRA 已聘请 Invitae 生殖健康销售代表 - NVTA** NVTA 称,该交易将有助于其削减运营开支,公司预计每年可从该交易中节省约 440 万美元,其中不包括一次性遣散费。** 2023 年 NVTA 股价下跌 66.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA","NVTA","BUZZ","BK4196","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.natera.com","stockEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.2646},{"period":"6month","weight":0.6565},{"period":"1year","weight":1.2677},{"period":"ytd","weight":0.762}],"compareEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":0.018},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.2262},{"period":"ytd","weight":0.1717}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Natera, Inc.于2007年1月在特拉华州成立。该公司是一个发展迅速的诊断公司且专有的分子生物学和生物信息学技术正在部署变更管理的遗传疾病。其新颖的分子检测能可靠地测量整个基因组区域的样本,小到一个单细胞。他们的统计算法结合这些测量,可以从更广泛的科学界提供数据,以检测各种最佳的一流的准确度和覆盖面严重情况。在产前检查空间,他们的技术已被证明有临床性和商业性。除了直接在美国的销售,该公司正在继续扩大,他们在全球有接近90个实验室和分销合作伙伴,包括许多大型的国际实验室。他们甚至能够更广泛地采用技术通过引入一个全球性的基于云的分布模型。该公司自2009推出七款分子诊断测试,他们打算在未来推出新产品,在产前检查和肿瘤领域。2013年三月,他们推出Panorama,一种无创性产前测试,或NIPT。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.035901},{"month":2,"riseRate":0.666667,"avgChangeRate":0.047896},{"month":3,"riseRate":0.555556,"avgChangeRate":0.016902},{"month":4,"riseRate":0.666667,"avgChangeRate":0.032843},{"month":5,"riseRate":0.777778,"avgChangeRate":0.104636},{"month":6,"riseRate":0.777778,"avgChangeRate":0.123586},{"month":7,"riseRate":0.555556,"avgChangeRate":0.032819},{"month":8,"riseRate":0.777778,"avgChangeRate":0.141187},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.063821},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.067699},{"month":11,"riseRate":0.444444,"avgChangeRate":0.05754},{"month":12,"riseRate":0.444444,"avgChangeRate":0.00988}],"exchange":"NASDAQ","name":"Natera, Inc.","nameEN":"Natera"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Natera, Inc.,NTRA,Natera, Inc.股票,Natera, Inc.股票老虎,Natera, Inc.股票老虎国际,Natera, Inc.行情,Natera, Inc.股票行情,Natera, Inc.股价,Natera, Inc.股市,Natera, Inc.股票价格,Natera, Inc.股票交易,Natera, Inc.股票购买,Natera, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}